Panacea Biotec has entered into long term agreement (LTA) with UNICEF for supply of Pentavalent Vaccine (Easyfive-TT) in calendar year 2017 and also received a Notification from Pan American Health Organization (PAHO) for purchase of Pentavalent Vaccine (Easyfive-TT) in the event PAHO should have any requirements through December 31, 2019.
Total value of this expected business from UN Agencies is worth $20.475 million equivalent to around Rs 140 crore based on current exchange rate.
Panacea Biotec is one of the India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
